USFDA conducted an inspection at Zydus Lifesciences Limited's manufacturing facility SEZ-1 at Pharmez, Ahmedabad from March 20 to March 24, 2023, the company announced through an exchange filing. The inspection was a pre-approval inspection (PAI) and a GMP Audit that concluded with three observations.
The company said that there were no data integrity related observations and the company is addressing these observations.
Zydus received final approval from USFDA for Lubiprostone Capsules, the company announced on March 24.
Zydus Lifesciences shares
Union Budget 2026–27 Allocates Record ₹2.93 Lakh Crore Capex To Railways, Unveils 7 High-Speed Corridors & New Freight Line
'Selling Chooran': PCB Accuses Indian Journalist Of Spreading Fake News Over India Match Boycott; Reporter Responds
Western Railway Announces 231 Holiday Special Trains To Manage Holi Festival Rush Across India
Hari Shankar Verma Assumes Charge As Member (Operations & Business Development) Of Railway Board
The shares of Zydus Lifesciences on Friday closed at Rs 480.05, down by 0.47 per cent.
